arrow
B

Brian G. Feagan

ica hn school of medicine at mount sinai
H指数:136
被引数:9.0万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Recommendations to Standardize the Conduct of Clinical Trials Evaluating Novel Therapies for Perianal Fistulizing Crohn’s Disease

关于标准化评估肛门瘘性克罗恩病新型疗法临床试验操作的建议

2025-11-190
PRE
Placebo rates in randomized clinical trials of ulcerative colitis: an individual patient data meta-analysis

溃疡性结肠炎随机临床试验中的安慰剂缓解率:一项基于个体患者数据的Meta分析

2025-10-010
OAAI
Reliability and Responsiveness of Endoscopic Indices for Assessing Crohn’s Disease Postoperative Recurrence in the PREVENT trial

PREVENT试验中用于评估克罗恩病术后复发的内镜指数的可靠性与反应性

2025-09-020
OAAI
Ustekinumab Intravenous Reinduction after Secondary Loss of Response in Patients with Crohn's Disease

乌司奴单抗静脉输注再诱导治疗克罗恩病患者二线应答丧失后的疗效

2025-09-010
OAAI
A Phase 2 Study of MORF-057, an Oral α4β7 Integrin Inhibitor in Moderately to Severely Active Ulcerative Colitis

一项关于MORF-057的II期研究,MORF-057是一种口服α4β7整合素抑制剂,用于中度至重度活动性溃疡性结肠炎。

2025-08-050
OAAI
Anti-TL1A antibody, afimkibart, in moderately-to-severely active ulcerative colitis (TUSCANY-2): a multicentre, double-blind, treat-through, multi-dose, randomised, placebo-controlled, phase 2b trial

抗TL1A抗体,afimkibart,在中度至重度活动性溃疡性结肠炎(TUSCANY-2):一项多中心、双盲、维持治疗、多剂量、随机、安慰剂对照的2b期试验

2025-07-210
PRE
1118a: A PHASE 2A, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY TO ASSESS THE SAFETY, PHARMACOKINETICS (PK) AND PHARMACODYNAMICS (PD) OF AGMB-129 IN PATIENTS WITH FIBROSTENOTIC CROHN’S DISEASE: INTERIM RESULTS FROM THE STENOVA TRIAL

1118a: 一项2A期、随机、安慰剂对照、双盲研究,旨在评估AGMB-129在纤维化狭窄型克罗恩病患者中的安全性、药代动力学(PK)和药效动力学(PD):STENOVA试验的期中结果

2025-07-030
PRE
Development and validation of a novel Endoscopic ulcer Activity Score for Evaluation of Crohn's Disease (EASE-CD) using data from two randomised controlled trials

开发并验证一种新型的内镜溃疡活动评分(EASE-CD)以评估克罗恩病,使用来自两项随机对照试验的数据

2025-06-090
PRE
Safety and efficacy of the anti-TL1A monoclonal antibody tulisokibart for Crohn's disease: a phase 2a induction trial

抗TL1A单克隆抗体tulisokibart治疗克罗恩病的有效性与安全性:一项2a期诱导试验

2025-05-300
PRE
An International Consensus on Appropriate Management of Corticosteroids in Clinical Trials in Inflammatory Bowel Disease

炎症性肠病临床试验中糖皮质激素适当管理的国际共识

2025-05-280
OAAI
Factors associated with response to filgotinib and the prognostic power of faecal calprotectin for ulcerative colitis in the phase 2b/3 SELECTION trial

与filgotinib应答相关的因素以及faecal calprotectin对溃疡性结肠炎的预后价值:SELECTION试验2b/3期研究

2025-05-150
OA
Expert recommendations to standardize transcriptomic analysis in inflammatory bowel disease clinical trials

专家建议标准化炎症性肠病临床试验中的转录组分析

2025-04-290
PRE
Association of bile acid diarrhea with symptoms and disease activity in Crohn's disease: post-hoc clinical trial analysis of serum 7a-hydroxy-4cholestern-3-one, C4, in patients with active Crohn's disease

胆汁酸腹泻与症状及疾病活动度的相关性:克罗恩病患者中血清7a-羟基-4-胆固醇-3-酮(C4)的后期临床试验分析

2025-04-090
PRE
Definitions, diagnosis, and management of postoperative recurrence in Crohn's disease patients with permanent ileostomy-a systematic review and meta-analysis

克罗恩病永久性回肠造口术后复发的定义、诊断和处理 -- 系统评价和荟萃分析

2025-04-010
PRE
Therapeutic Drug Monitoring for Dose Optimization of Infliximab in Patients With Inflammatory Bowel Disease: An Analysis of Canadian Real-World Data

炎症性肠病患者英夫利昔定制量优化的治疗药物监测:加拿大真实世界数据分析

2025-02-060
OA